Go back

EU updates incidence management plan for medicines

The European Medicines Agency has amended its incidence management plan for medicines to reflect changes in EU legislation that covers the safety of medicines.

The incidence plan, which has been in operation since 2009, explains how the EMA, the European Commission and member state regulatory authorities respond to new events or information concerning previously authorised medicines. Such developments often relate to pharmacovigilance, the ongoing monitoring of the safety of medicines on the market.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.